[Spectrum of erythrocyte membrane lipids in various types of hypoglycemic therapy].
Changes in the lipid spectrum of red cell membrane (cholesterol, total and fractional phospholipids) were examined in 46 patients with newly detected non-insulin-dependent diabetes mellitus at the period of the disease diagnosis and over the course of therapy with various sugar-reducing drugs. Diabeton, a gliclazide series drug, has shown the most manifest compensatory effect on red cell membrane lipid shifts. Diets and biguanide therapy for 6-8 months failed to stably normalize the detected shifts; further correction appeared to be necessary in such cases.
G S
GS
Kozlov
T A
TA
Buĭdina
M I
MI
Balabolkin
D001645:Biguanides / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D002845:Chromatography; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D004910:Erythrocyte Membrane / Q000032:analysis*; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008563:Membrane Lipids / Q000032:analysis*; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood
D001645:Biguanides; D007004:Hypoglycemic Agents; D008563:Membrane Lipids; D010743:Phospholipids; D002784:Cholesterol; D005907:Gliclazide
Lipidnyĭ spektr éritrotsitarnoĭ membrany pri razlichnykh vidakh sakharosnizhaiushcheĭ terapii.